Publications by authors named "Moises Marin"
Although previous studies have assessed the clinical or economic value of specific technologies, the economic value of improving sensitivity for malignancy in lung cancer diagnoses broadly across technologies is unclear. To identify the economic value of improving sensitivity of bronchoscopy biopsy for the diagnosis of lung cancer. A decision analytic model was developed to quantify the economic value of increased sensitivity for malignancy for bronchoscopy biopsy of peripheral pulmonary lesions.
View Article and Find Full Text PDFArticle Synopsis
- - The study evaluated the benefits of increasing lung cancer screening rates for high-risk individuals and its effects on health disparities, using a model based on data from 2017-2019.
- - Findings revealed that compliance with screening guidelines was higher among low-income and less-educated groups, while increasing screening to 100% could yield a cost-effective benefit of $64,654 per quality-adjusted life-year and $182.1 billion in total economic value for the U.S.
- - The analysis highlighted that up to 32.2% of this economic value comes from reductions in health disparities, suggesting that policymakers and clinicians might overlook important benefits when they don't factor in these disparities in their decisions.
Objectives: This study aimed to estimate the incremental health benefits of pharmaceutical innovations approved between 2011 and 2021 and the share that would surpass the National Institute for Health and Care Excellence (NICE) "size of benefit" decision weight thresholds.
Methods: We identified all US-approved drugs between 2011 and 2021. Health benefits, in terms of quality-adjusted life-years (QALYs) for each treatment, were extracted from published cost-effectiveness analyses.